Other Techniques written and compiled by doctordee | Search LMS site |

Other Useful Techniques Access to Investigational Drugs--Compassionate Use Vaccines Targeted Molecular Therapy
Other Useful Techniques
Is there other information you would like to see on this website? If so, Contact Us OR Subscribe to the ACOR L-M-Sarcoma List and tell us online.
Access to Investigational Drugs--Compassionate Use
Access to Investigational Drugs: Questions and Answers What is an investigational drug? An investigational drug is one that is under study but does not yet have permission from the Food and Drug Administration (FDA) to be legally marketed and sold in the United States. FDA approval is the final step in the process of drug development. The first step in the process is for the new drug to be tested in the laboratory. If the results are promising, the drug company or sponsor must apply for FDA approval to test the drug in people. This is called an Investigational New Drug (IND) Application. Once the IND is approved, clinical trials can begin. Clinical trials are research studies to determine the safety and measure the effectiveness of the drug in people. Once clinical trials are completed, the sponsor submits the study results in a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA. This application is carefully reviewed and, if the drug is found to be reasonably safe and effective, it is approved. How do patients get investigational drugs? By far, the most common way that patients get investigational drugs is by participating in a clinical trial sponsored under an IND. A patient’s doctor may suggest participation in a clinical trial as one treatment option. Or a patient or family member can ask the doctor about clinical trials or new drugs available for cancer treatment. Another way of learning about new drugs being tested in clinical trials is through the National Cancer Institute’s (NCI) PDQ® database. This database contains information on a large number of ongoing studies. Individuals can search this Clinical Trials Database on their own or they can call the NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). Information specialists can search the database and provide a list of trials for individuals to share with their doctor. Are there other ways to get investigational drugs? Less common ways that patients can receive investigational drugs are through an expanded access protocol or by a mechanism known as a special or compassionate exception. Expanded Access Expanded access protocols are available for a limited number of investigational drugs that have been well studied and are awaiting final FDA approval for marketing. Expanded access allows a wider group of people to be treated with the drug. The purpose of an expanded access program is to make investigational drugs that have significant activity against specific cancers available to patients before the FDA approval process has been completed. The drug company or IND sponsor must apply to the FDA to make the drug available through an expanded access program. There must be enough evidence from studies already completed to show that the drug may be effective to treat a specific type of cancer and that it does not have unreasonable risks. The FDA generally approves expanded access only if there are no other satisfactory treatments available for the disease. Special Exception/Compassionate Exemption Patients who do not meet the eligibility criteria for a clinical trial of an investigational drug may be eligible to receive the drug under a mechanism known as a special exception or a compassionate exemption to the policy of administering investigational drugs only in a clinical trial. The patient’s doctor contacts the sponsor of the investigational agent and provides the patient’s medical information and treatment history; requests are evaluated on a case-by-case basis. The FDA must approve each request to provide the drug outside a clinical trial. There should be reasonable expectation that the drug will prolong survival or improve quality of life. These are some questions that are considered when determining if a patient may be a candidate to receive an investigational drug as a special exception: Is the patient ineligible for a clinical trial? Have standard therapies been exhausted? Is there objective evidence that the investigational agent is active in the disease for which the request is being made? Can the drug potentially benefit the patient? What is the risk to the patient? In some cases, even patients who qualify for treatment with an investigational drug on a "compassionate basis" might not be able to obtain it if the drug is in limited quantity and high demand. Are all investigational drugs available through an expanded access or special exception mechanism? No. The drug company or sponsor decides whether to provide an investigational drug outside the clinical trial setting. Availability may be limited in part by drug supply, patient demand, or other factors. What is the NCI’s role in providing access to investigational drugs? The NCI acts as the sponsor for many, but not all, investigational drugs. When acting as sponsor, the NCI provides the investigational drug to the physicians who are participating in clinical trials of the drug. A physician who wishes to treat a patient with the investigational drug as a special exception must request the drug from the NCI. The request must include the patient’s age, sex, diagnosis, date of diagnosis, previous cancer therapy, current clinical status, intended dose and schedule of the requested drug, any proposed concomitant cancer drugs or other therapies, and pertinent laboratory data. These requests are reviewed on a case-by-case basis. Who can provide access to investigational drugs being developed by pharmaceutical companies? In the case of investigational drugs sponsored by a drug company, the drug company in collaboration with the FDA provides access to the drug. The process is similar to that described above. A request to treat a patient with an investigational drug outside a clinical trial must be made to the drug company and to the FDA. The request to the FDA is sent as general correspondence to the appropriate reviewing division where the IND application is filed. The drug company can provide the name of the appropriate reviewing division. (FDA reviewing divisions are prohibited from divulging proprietary information such as whether a sponsor has filed an IND or the status of an IND.) Are there specific criteria used to determine whether patients can receive an investigational drug outside the clinical trial setting? Generally, patients must meet the following criteria to be considered for treatment with an investigational drug outside the clinical trial setting: *have undergone standard treatment that has not been successful be ineligible for any ongoing clinical trials *have a cancer diagnosis for which an investigational drug has demonstrated activity and is being studied in ongoing Phase 2 or Phase 3 protocols *The potential benefits of receiving the drug should outweigh the risks involved. What should patients do if they are interested in receiving an investigational drug through a special exception or expanded access mechanism? Patients interested in gaining access to investigational drugs should talk to their physician about available options. Physicians can make requests for special exceptions by contacting the study sponsor. Physicians will be required to follow strict guidelines, including gaining approval from their Institutional Review Board and obtaining informed consent from the patient. Informed consent is a process that includes a document to be signed by the patient which outlines the known risks and benefits of the treatment, as well as the rights and responsibilities of the patient. What are the costs involved in receiving an investigational drug? In general, the drug is provided free of charge. However, there may be other costs associated with the treatment. Patients should check with their insurer about coverage of these costs prior to beginning treatment. What are some of the potential drawbacks to receiving an investigational drug? There are some potential drawbacks to receiving an investigational drug. *It is not known whether an investigational drug is better than standard therapy for treating a disease, and a patient who is receiving an investigational drug may not receive any benefit from it. *Side effects (both long-term and short-term) from the drug may not be fully understood, especially if the drug is in early phases of testing. *Finally, a patient’s health insurance company may not pay expenses associated with receiving the investigational drug. How can patients find out more information about a specific investigational drug? Patients can find out more about a specific drug by contacting the drug company that is developing the drug. Information may also be available from the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). What other resources are available on this topic? The following list of resources may be helpful: 1. NCI’s Cancer.gov Web site has a feature titled nderstanding the Approval Process for New Cancer Drugs: Summary, which can be found at Approval Process. 2. FDA Center for Drug Evaluation and Research Web site has Oncology Tools, which contains a variety of information related to cancer including a section on Access to Trial Drugs. 3. CTEP (the Cancer Therapy Evaluation Program at NCI) has a Web site titled Developing Cancer Therapies. Sources of National Cancer Institute Information *Cancer Information Service Toll-free: 1-800-4-CANCER (1-800-422-6237) *TTY (for deaf and hard of hearing callers): 1-800-332-8615 NCI *Online Internet NCI Website. *LiveHelp Cancer Information Specialists offer online assistance through the LiveHelp link on the NCI's Web site. Editorial changes made: 06/12/2002 by NCI The Federal Drug Administration & Access to Clinical Trial Drugs We recommend that you go to FDA's Access to Unapproved Products for the latest update on FDA regulations. Access to Unapproved Drugs Access to unapproved drugs can occur through many legal mechanisms, including enrolling in clinical trials, a special exception or compassionate exemption, an emergency Investigational New Drug (IND), and a Treatment IND. One of the most common methods to have access to an unapproved drug is to enroll in a clinical trial. There are many sources of information about clinical trials. One of the best methods is to ask a physician who specializes in the care of cancer patients. There are two pages in this Oncology Tools site where there are listings of clinical trials, Regulatory Tools and Oncology Web Sites. These listings are provided as a convenience, and no FDA endorsement should be implied.. Other resources are the Cancer Information Service of the National Cancer Institute (NCI) at 1-800-4CANCER (1-800-422-6237) or visit the NCI online at Cancernet and look at the Clinical Trials section on the first page. If the eligibility criteria in a study protocol are not suitable for a particular patient, it may still be possible to be treated according to the study protocol as a special exception (sometimes called compassionate exemption). Treating a patient as an exception is at the discretion of the investigator and sponsor, and usually requires filing extra paperwork, including sending a request to the FDA, modifying the consent form and obtaining permission from the local Institutional Review Board (IRB). The request letter should state the rationale for requesting the exception and provide a brief patient history. It is sent as general correspondence to the appropriate Investigational New Drug (IND) application. Once an investigator and sponsor agree, further advice may be obtained by contacting the FDA review division where the IND is filed. The drug supplier should be able to provide the name of the appropriate review division. FDA review divisions are prohibited from divulging proprietary information such as whether a sponsor has filed an IND or the status of an IND. Not all protocols are listed on the internet lists, and if there is interest in a particular drug (or biological or device), contacting the sponsor or manufacturer directly may help locate a facility that can provide access. Another alternative is for a physician to file a single patient or emergency IND directly with the FDA. This must be done with the cooperation and permission of the drug supplier. Follow these links for general procedures and guidelines, and instructions on formatting a request for a single patient IND, although it is generally helpful to get specific advice by contacting the FDA review division where the drug supplier's IND is to be filed. The drug supplier should be able to provide the name of the appropriate review division. FDA review divisions are prohibited from divulging proprietary information such as whether a sponsor has filed an IND or the status of an IND. Filing a single patient or emergency IND has the same responsibilities as any IND in that the local Institutional Review Board (IRB) must be notified and approve, and adverse events, clinical updates, and an annual report must be filed with the FDA. Sponsors may not charge for unapproved drugs, although there may be charges by a treating facility for costs associated with the administration of the drug and the general care of the patient. There is an exception through a mechanism called a treatment IND. Under this program, a sponsor of a drug that has shown clinical promise and is currently under review by the FDA may charge for the drug during the review process if permission has been obtained from the FDA. The intent of the program is to reimburse a sponsor for costs associated with providing expanded access to the drug prior to commercial distribution. FDA/Center for Drug Evaluation and Research Last Updated: 10/29/2003

The information on this site is not a substitute for professional medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting with your doctor. Please consult your doctor with any questions or concerns you may have regarding your condition. Copyright © 2001-2006 LMSWEBSITE